Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory conditions
Biotech
Merck bags $700M from Blackstone, spends $150M to regain asset
Merck is paying $150 million upfront for full control of an early-phase asset and pocketing $700 million to fund an expansive pivotal oncology push.
Nick Paul Taylor
Nov 4, 2025 9:15am
Sitala seals $670M deal for Fosun immune disease drug
Aug 26, 2025 2:44pm
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm
MoonLake's IL-17 drug wins 'meet or beat' trial vs. competition
Jun 26, 2023 11:18am
Aclaris stock sinks after phase 2a skin trial flop
Mar 6, 2023 11:29am
Manufacturing concerns sideline INmune's US Alzheimer's trial
May 24, 2022 9:44am
